FDA Clearance Tracker · P160052-S001
PartoSure Test
Last checked: Nov 20, 2026Latest source record: Oct 11, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Oct 11, 2019
Approved
Time to decision
518 days
Received May 11, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P160052-S001
- Device name
- PartoSure Test
- Applicant
- Qiagen, Inc.
- Applicant location
- Germantown, MD
- Received
- May 11, 2018
- Decided
- Oct 11, 2019
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P160052
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval of the revised protocol for the post-approval study (PAS) protocol
Source documents
Other decisions for Qiagen, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P160052 · Decided Apr 11, 2018 · 497 days after receipt
Device type: Placental alpha microglobulin-1 immunoassay (QBB) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.